Raptor Pharmaceutical Corp (NASDAQ: RPTP) and Alder BioPharmaceuticals (NASDAQ:ALDR) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Profitability

This table compares Raptor Pharmaceutical Corp and Alder BioPharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Raptor Pharmaceutical Corp -43.75% -77.01% -15.64%
Alder BioPharmaceuticals N/A -78.68% -72.72%

Analyst Recommendations

This is a summary of recent recommendations for Raptor Pharmaceutical Corp and Alder BioPharmaceuticals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Raptor Pharmaceutical Corp 0 3 0 0 2.00
Alder BioPharmaceuticals 0 1 9 0 2.90

Raptor Pharmaceutical Corp currently has a consensus price target of $7.67, indicating a potential downside of 14.81%. Alder BioPharmaceuticals has a consensus price target of $36.90, indicating a potential upside of 312.29%. Given Alder BioPharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Alder BioPharmaceuticals is more favorable than Raptor Pharmaceutical Corp.

Volatility and Risk

Raptor Pharmaceutical Corp has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, Alder BioPharmaceuticals has a beta of 2.53, meaning that its share price is 153% more volatile than the S&P 500.

Earnings and Valuation

This table compares Raptor Pharmaceutical Corp and Alder BioPharmaceuticals’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Raptor Pharmaceutical Corp N/A N/A N/A ($1.03) -8.74
Alder BioPharmaceuticals $683,000.00 887.31 -$257.76 million ($5.14) -1.74

Raptor Pharmaceutical Corp has higher revenue, but lower earnings than Alder BioPharmaceuticals. Raptor Pharmaceutical Corp is trading at a lower price-to-earnings ratio than Alder BioPharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

54.9% of Raptor Pharmaceutical Corp shares are owned by institutional investors. Comparatively, 78.8% of Alder BioPharmaceuticals shares are owned by institutional investors. 5.6% of Raptor Pharmaceutical Corp shares are owned by company insiders. Comparatively, 10.6% of Alder BioPharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Alder BioPharmaceuticals beats Raptor Pharmaceutical Corp on 8 of the 11 factors compared between the two stocks.

About Raptor Pharmaceutical Corp

Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years. In Europe, PROCYSBI gastro-resistant hard capsules of cysteamine (as mercaptamine bitartrate), is indicated as an orphan medicinal product for the management of nephropathic cystinosis. Its QUINSAIR is a formulation of the antibiotic drug levofloxacin, suitable for inhalation via a nebulizer. It is engaged in developing MP-376 for non-CF bronchiectasis (BE) and nontuberculous mycobacteria (NTM) lung infections. It is also engaged in developing RP105 and RP106 for various diseases.

About Alder BioPharmaceuticals

Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder’s third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc.

Receive News & Ratings for Raptor Pharmaceutical Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Raptor Pharmaceutical Corp and related companies with MarketBeat.com's FREE daily email newsletter.